Your browser doesn't support javascript.
loading
Therapeutic response to artemisinin combination therapies among individuals with Plasmodium falciparum single infection vs mixed Plasmodium species infections: a retrospective posthoc analysis in Kisumu County, western Kenya.
Chemwor, Gladys C; Andagalu, Ben M; Onyango, Irene A; Opot, Benjamin H; Okoth, Raphael O; Yedah, Redemptah A; Juma, Jackline A; Mwakio, Edwin W; Wakoli, Dancan M; Amwoma, Joseph G; Cheruiyot, Agnes C; Juma, Dennis W; Ogutu, Bernhards R; Egbo, Timothy E; Garges, Eric C; Roth, Amanda L; Kamau, Edwin; Watson, Oliver J; Akala, Hoseah M.
Afiliação
  • Chemwor GC; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Andagalu BM; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Onyango IA; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Opot BH; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Okoth RO; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Yedah RA; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Juma JA; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Mwakio EW; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Wakoli DM; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Amwoma JG; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Cheruiyot AC; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Juma DW; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya.
  • Ogutu BR; Centre for Clinical Research, Kenya Medical Research Institute, 1578-40100 Kisumu-Kakamega Road, Kisumu, Kenya; Centre for Research in Therapeutic Sciences (CREATES), Strathmore University, P.O. Box 59857, 00200, City Square, Nairobi, Kenya.
  • Egbo TE; United States Army Medical Research Directorate-Africa, (USAMRD-A), P.O. Box 606, 00621 Village Market, Nairobi, Kenya.
  • Garges EC; United States Army Medical Research Directorate-Africa, (USAMRD-A), P.O. Box 606, 00621 Village Market, Nairobi, Kenya.
  • Roth AL; United States Army Medical Research Directorate-Africa, (USAMRD-A), P.O. Box 606, 00621 Village Market, Nairobi, Kenya; Medical Communications for Combat Casualty Care, 1545 Porter St, Fort Detrick, Maryland, 21702, USA.
  • Kamau E; United States Army Medical Research Directorate-Africa, (USAMRD-A), P.O. Box 606, 00621 Village Market, Nairobi, Kenya; Department of Pathology and Area Laboratory Services, Tripler Army Medical Center, 1 Jarrett White Rd, Honolulu, HI 96859, Honolulu, USA.
  • Watson OJ; Medical Research Council, Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, UK.
  • Akala HM; Department of Emerging and Infectious Diseases (DEID), United States Army Medical Research Directorate-Africa (USAMRD-A), Kenya Medical Research Institute (KEMRI)/Walter Reed Project, P. O. Box 54 - 40100, Kisumu, Kenya. Electronic address: hoseaakala@yahoo.com.
Int J Infect Dis ; 132: 17-25, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37061211
ABSTRACT

OBJECTIVES:

This study examined the treatment response of mixed vs single-species Plasmodium falciparum infections to artemisinin-based combination therapies (ACTs).

METHODS:

A total of 1211 blood samples collected on days 0, 7, 14, 21, 28, 35, and 42 from 173 individuals enrolled in two randomized ACT efficacy studies were tested for malaria using 18s ribosomal RNA-based real-time polymerase chain reaction. All recurrent parasitemia were characterized for Plasmodium species composition and time to reinfection during 42-day follow-up compared across ACTs.

RESULTS:

Day 0 samples had 71.1% (116/163) single P. falciparum infections and 28.2% (46/163) coinfections. A total of 54.0% (88/163) of individuals tested positive for Plasmodium at least once between days 7-42. A total of 19.3% (17/88) of individuals with recurrent infections were infected with a different Plasmodium species than observed at day 0, with 76.5% (13/17) of these "hidden" infections appearing after clearing P. falciparum present at day 0. Artesunate-mefloquine (16.4 hours) and dihydroartemisinin-piperaquine (17.6 hours) had increased clearance rates over artemether-lumefantrine (21.0 hours). Dihydroartemisinin-piperaquine exhibited the longest duration of reinfection prophylaxis. Cure rates were comparable across each species composition.

CONCLUSION:

No differences in clearance rates were found depending on whether the infection contained species other than P. falciparum. Significantly longer durations of protection were observed for individuals treated with dihydroartemisinin-piperaquine.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 / 3_ND Problema de saúde: 2_enfermedades_transmissibles / 3_malaria / 3_neglected_diseases Assunto principal: Quinolinas / Malária Falciparum / Artemisininas / Malária / Antimaláricos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Int J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Quênia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 / 3_ND Problema de saúde: 2_enfermedades_transmissibles / 3_malaria / 3_neglected_diseases Assunto principal: Quinolinas / Malária Falciparum / Artemisininas / Malária / Antimaláricos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Int J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Quênia